Interpace Biosciences targets Nasdaq uplisting with 1-for-5 reverse stock split - IDXG News | RalliesInterpace Biosciences targets Nasdaq uplisting with 1-for-5 reverse stock split
I
IDXG• Reverse split set ahead of proposed Nasdaq uplisting
- Interpace Biosciences set a 1-for-5 reverse stock split effective Aug. 27 to support a proposed Nasdaq uplisting.
- Shares are to trade split-adjusted on OTCID at the open on Aug. 27; the ticker is to switch temporarily to IDXGD for 20 sessions.
- Outstanding shares are to drop to about 5,500,000 from about 27,700,000; the authorized share count is unchanged.
- Nasdaq bid-price compliance is the primary goal; additional listing hurdles remain, including a $15 million public float threshold.
•
